Q1 Earnings Estimate for NERV Issued By HC Wainwright

Minerva Neurosciences, Inc (NASDAQ:NERV) – Analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Minerva Neurosciences in a research note issued to investors on Thursday, November 6th. HC Wainwright analyst D. Tsao anticipates that the biopharmaceutical company will post earnings per share of ($0.14) for the quarter. HC Wainwright has a “Neutral” rating and a $4.00 price target on the stock. The consensus estimate for Minerva Neurosciences’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Minerva Neurosciences’ Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.09) EPS and FY2029 earnings at $0.61 EPS.

Separately, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Minerva Neurosciences in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce” and an average price target of $4.00.

Minerva Neurosciences Trading Down 0.1%

Shares of NASDAQ NERV traded down $0.01 during midday trading on Friday, hitting $3.64. The stock had a trading volume of 12,111 shares, compared to its average volume of 903,824. The business’s 50 day moving average is $2.84 and its 200-day moving average is $2.17. Minerva Neurosciences has a 52 week low of $1.15 and a 52 week high of $12.46.

Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.01).

Institutional Investors Weigh In On Minerva Neurosciences

An institutional investor recently raised its position in Minerva Neurosciences stock. Apella Capital LLC raised its holdings in shares of Minerva Neurosciences, Inc (NASDAQ:NERV) by 87.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 39,314 shares of the biopharmaceutical company’s stock after purchasing an additional 18,375 shares during the quarter. Apella Capital LLC’s holdings in Minerva Neurosciences were worth $83,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 34.56% of the company’s stock.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.